158 results about "Struma ovarii" patented technology

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the proapoptotic caspase adaptor protein (=PACAP) as a universal marker of different types of cancer. PACAP aids in the assessment of pulmonary or lung cancer (LC), particularly of non-small cell lung carcinoma (NSCLC), but also of other specific types of cancer. Such specific types of cancer are e.g. colon, bladder, cervix, ovary, endometrial, head and neck, breast, melanoma, pancreas, kidney, prostate, esophagus, stomach or bile duct cancer. Furthermore, the present invention especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring PACAP in said sample. Measurement of PACAP can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.

Autotaxin (ATX) is a prometastatic enzyme initially isolated from the conditioned media of human melanoma cells that stimulates a myriad of biological activities including angiogenesis and the promotion of cell growth, survival, and differentiation through the production of lysophosphatidic acid (LPA). ATX increases the aggressiveness and invasiveness of transformed cells, and ATX levels directly correlate with tumor stage and grade in several human malignancies. To study the role of ATX in the pathogenesis of malignant melanoma, we developed antibodies and small molecule inhibitors against recombinant human protein. Immunohistochemistry of paraffin embedded human tissue demonstrates that ATX levels are markedly increased in human primary and metastatic melanoma relative to benign nevi. Chemical screens identified several small molecule inhibitors with binding constants ranging from nanomolar to low micromolar. Cell migration and invasion assays with melanoma cell lines demonstrate that ATX markedly stimulates melanoma cell migration and invasion, an effect suppressed by ATX inhibitors. The migratory phenotype can be rescued by the addition of ATX's enzymatic product, LPA, confirming that the observed inhibition is linked to suppression of LPA production by ATX. Chemical analogues of the inhibitors demonstrate structure activity relationships important for ATX inhibition and indicate pathways for their optimization. These studies suggest that ATX is an approachable molecular target for the rational design of chemotherapeutic agents directed against human malignancies driven by the ATX / LPA axis, especially including malignant melanoma, among numerous others including breast and ovarian cancers.

Methods for treating or reducing the likelihood of acquiring estrogen-related (e.g. estrogen-exacerbated) diseases including endometriosis include administering to a patient a selective estrogen receptor modulator (SERM), in combination with inhibiting ovarian secretions, e.g., by administering an LHRH agonist or antagonist. In some embodiments, a precursor of sex steroids, said precursor being selected from the group consisting of dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S), androst-5-ene-3β,17β-diol (5-diol), and androstenedione or a compound transformed into one of these, is also administered

One aspect of the present invention is concerned with a method of controlled ovarian hyperstimulation in a mammalian female, said method comprising the co-administration to said female of —a substance having follicle stimulating hormone activity (FSH substance) in an amount effective to stimulate multiple follicular development; —gonadotropin releasing hormone (GnRH) antagonist in an amount equivalent to a daily subcutaneous dose of at least 0.5 mg ganirelix to prevent a premature LH-surge; and —a LH substance in an amount effective to prevent or suppress symptoms of luteinising hormone (LH) deficiency resulting from the administration of the GnRH antagonist; followed by administering a meiosis and luteinisation inducing substance (ML substance) in an amount effective to stimulate resumption of meiosis and luteinisation, and wherein the LH substance is not obtained from the urine of human females. Another aspect of the to invention relates to a pharmaceutical kit for use in a method of controlled hyperstimulation, which kit comprises: —at least one parenteral or oral dosage unit containing one or more FSH substances in an amount equivalent to a subcutaneous dose of 50-1500 I.U. FSH; —at least one parenteral dosage unit containing one or more GnRH antagonists in an amount equivalent to a subcutaneous dose of 0.5-25 mg ganirelix; —at least one parenteral dosage unit containing one or more LH substances in an amount equivalent to a subcutaneous dose of 50-3000 I.U. recombinant LH; wherein the LH substance is not obtained from the urine of human females.

The present invention provides assay systems and methods for determining the percent fetal contribution of cell-free DNA in a maternal sample from a pregnant female with an egg donor pregnancy. Further provided, are assay systems and methods for determining a statistical likelihood of the presence or absence of a fetal aneuploidy in a maternal sample using a determined percent fetal cell-free DNA in the sample.

The invention discloses application of a NlInR gene of brown planthopper as a target point in preparation of a pesticide for preventing and treating the brown planthopper, and provides dsRNA used forinhibiting expression of the NlInR gene, wherein the NlInR gene is composed of a NlInR1 gene and a NlInR2 gene; the nucleotide sequence of the NlInR1 gene is shown as SEQ ID NO.1; the nucleotide sequence of the NlInR2 gene is shown as SEQ ID NO.2. The effect of the NlInR gene in preventing and treating the brown planthopper is discovered for the first time, the dsRNA of the NlInR gene is obtainedthrough an RNAi technology, and after the NlInR gene is silenced through a micro-injection mode, the individual development and the ovarian development of the brown planthopper can be effectively inhibited, and the spawning amount is reduced, so that the propagation of the brown planthopper is inhibited, and the prevention and treatment of the brown planthopper are realized.

The invention relates to a method for treating premature ovarian failure by virtue of placenta mesenchymal stem cells and a cell preparation and particularly relates to the cell preparation on one hand. The cell preparation is cell suspension prepared by mixing mesenchymal stem cells such as placenta mesenchymal stem cells into a 0.9% sodium chloride solution and is particularly prepared by the steps of transferring mesenchymal stem cells obtained through cell passage into a centrifuge tube, carrying out centrifuging to remove supernatant, adding the 0.9% sodium chloride solution, and carryingout resuspension, so as to obtain the cell preparation. The mesenchymal stem cells are prepared by the steps of processing placental lobules, carrying out digestion and termination on mixed enzyme, collecting primary cells, carrying out cryopreservation on the primary cells, carrying out thawing, passage, detection and cryopreservation on the cells, and relating with a database. The cell preparation prepared by virtue of the method presents excellent biological effect in the treatment of the premature ovarian failure.

A glycoside extract DSS-A-N-30 of an anoelica sinensis herbaceous peony prescription comprises an integral glycoside (herbaceous peony glycoside and white peony root glycoside) of 36.0-44.0 of the weight percentage calculated by the weight of the extract, wherein the anoelica sinensis herbaceous peony prescription comprises anoelica sinensis, herbaceous peony, poria cocos wolf, white atractylodes rhizome, rhizoma alismatis, and chuanxiong rhizome of which the weight proportion of the compatibility is 3:16:4:4:8:8. The products or the medicament compositions with the extract are used as the products or the medicament purposes for curing the diseases which are related with the ache, senescence, and hypofunction and disorder of reproductive endocrine, in particular to dysmenorrheal, unregulated menstrual flow, abortion, climacteric metancholia, senile dementia, hypofunction of ootheca and the like.

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., glioblastoma and ovarian hyperstimulation syndrome. The invention provides, inter alia, methods of treating or controlling a disease condition mediated by an aquaporin, e.g., diseases or conditions of water imbalance and other diseases.

The invention relates to a placental mesenchymal stem cell preparation used for treating premature ovarian failure. Particularly, one the one hand, the method that mesenchymal stem cells are separatedfrom placenta tissue and cultured into the mesenchymal stem cells is provided; on the other hand, the cell preparation is provided, wherein the cell preparation is a cell suspension which is preparedin the step that the mesenchymal stem cells, such as placental mesenchymal stem cells, are mixed and suspended into a 0.9% sodium chloride solution. The cell preparation can be used for treating thepremature ovarian failure; particularly, the cell preparation is the placental mesenchymal stem cell preparation. The cell preparation is prepared by using the method including the steps that the mesenchymal stem cells obtained through cell passage are transferred into a centrifuge tube and centrifuged, liquid supernatant is removed, a 0.9% sodium chloride solution is added for resuspension, and the cell preparation is prepared. The cell preparation has an excellent biological effect on treatment of the premature ovarian failure.

Methods for the treatment of patients with HER2-positive, HER2-amplified and / or HER2-mutated advanced cancer by administration of pertuzumab plus trastuzumab are disclosed. In one aspect, the cancer is advanced HER2-positive, HER2-amplified and / or HER2-mutated colorectal, biliary, bladder, urothelial, salivary, lung, pancreatic, ovarian, prostate, or skin cancer. In another aspect, the cancer is HER2-positive, HER2-amplified and / or HER2-mutated colorectal, biliary, bladder, urothelial, salivary, lung, pancreatic, ovarian, prostate, or skin cancer that is refractory to one or more other treatment regimens.

The invention discloses an application of STAT3 in porcine ovarian granulosa cells. STAT3 is taken as a research object, and a porcine STAT3 gene promoter double-luciferase reporter gene recombinationplasmid is constructed, and the core promoter region of the STAT3 is found through the expression activity of the STAT3 gene promoter in the porcine ovarian granulosa cell; and then the interaction between the transcription factor C / EBP beta and the core promoter region of the STAT3 is verified; then C / EBP beta superexpression vector is constructed and small interfering RNA (C / EBP beta-siRNA) issynthesized, the effect of C / EBP beta on STAT3 is detected, finally, the expression vector of C / EBP beta and C / EBP beta-siRNA were transfected respectively to the granulosa cells in order to detect the apoptosis and proliferation of the cells. The application of STAT3 in porcine ovarian granulosa cells finds the application of the transcription factor C / EBP beta in the ovarian granulosa cell by finding the transcription factor C / EBP beta in the STAT3 promoter region, and has good application value for researching the ovarian follicular atresia mechanism.

The invention discloses an application of a DNMT1 gene in porcine ovarian granulosa cells, belonging to the technical fields of cell engineering and gene engineering. According to the invention, the influence of DNMT1 on pGCs proliferation, apoptosis and E2 secretion is explored from a cellular level and a molecular level by taking a catalytic enzyme DNMT1 formed by DNA methylation as an entry point. Results show that the DNMT1 gene participates in promotion of proliferation of granulosa cells and E2 secretion and inhibition of apoptosis and maturation of the granulosa cells. The invention provides an important value for researching the influence mechanism of DNA methylation on ovarian follicle development and sow reproductive performance.

The invention discloses application of a RBP1 gene in sow ovarian granular cells. RBP1 is taken as a research object, and a molecular and cell biological method is adopted to study the application ofthe RBP1 in sow ovarian granular cells. The molecular and cell biological method includes the following steps that through ChIP-Seq, it is found that the enrichment degree of H3K4me3 is different in RBP1 gene promoter regions in follicles different in size; through qRT-PCR, it is found that the expression quantity of the RBP1 gene in follicles different in size is different significantly. By promoting or inhibiting the enrichment degree of H3K4me3 in the sow ovarian granular cells, it is found that promotion of the enrichment degree of H3K4me3 can promote transcription of the RBP1 gene, and inhibition of the enrichment degree of H3K4me3 can inhibit transcription of the RBP1 gene; through RBP1 over-expression or interference with RBP1, it is found that RBP1 can promote proliferation of thesow ovarian granular cells and inhibit apoptosis.

Method of early detection of risk of infertility and ovarian aging in and treatment of a human female who has not experienced infertility and is not otherwise indicated to have premature ovarian aging. A number of CGG repeats on each allele of the isolated FMR1 gene is measured by using an assay, and a testing regimen is performed only when the determined number of CGG repeats on one of the FMR1 gene alleles is less than 26. The testing regimen includes periodically measuring serum level of a hormone related to fertility, such as Anti-Müllerian Hormone, Follicle Stimulating Hormone and / or estradiol over a period of about three to eight years and, after each measurement, determining if the measured serum level is less than a set confidence interval for a human female of the same age of the female. If so, the human female is treated for premature ovarian aging.

The invention discloses a polypeptide for treating osteoporosis, wherein the amino acid sequence is (Asp-Ser-Ser)6-(D-Tyr)-Asn-(D-Trp)-Asn-Ser-Phe-(azaGly)-Leu-Arg(Me)-Phe-NH2((AspSerSer)6-Kp-10, SEQID NO:1). The present invention further discloses a preparation method of the polypeptide, wherein the preparation method comprises: polypeptide synthesis, polypeptide cleavage, and separation and purification of the crude polypeptide. The invention further relates to applications of the polypeptide in preparation of drugs for treatment of osteoporosis. According to the present invention, the research results prove that the knockout of the Gpr54 or Kiss1 gene can cause osteoporosis and excessive activation of osteoclasts, Kp-10 inhibits osteoclast differentiation, actin-ring formation and boneresorption by activating Gpr54, and (AspSerSer)6-Kp-10 has good bone targeting effect and cab effectively treat ovariectomy induced osteoporosis in vivo compared to Kp-10, such that the theoretical basis is provided for the treatment of osteoclast-related diseases.

The invention relates to a method for slowing down ovarian surface epithelial cell vicious transformation. During ovarian surface epithelial cell vicious transformation, active vitamin D (1,25(OH)2D3) is added through each passage and after each culture medium replacement so as to slow down the ovarian surface epithelial cell vicious transformation. The invention further provides application of the vitamin D in the preparation of medicine for treating ovarian cancer. By the long-term use of low dosage of vitamin D, 25-hydroxyvitamin D or active vitamin D, the tumorigenic ability of ovarian surface epithelial cells in the body of a nude mouse can be weakened effectively.

The invention relates to a traditional Chinese medicine composition for treating premature ovarian failure. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10 to 15 parts of fructus ligustri lucidi, 10 to 15 parts of mulberries, 10 to 15 parts of semen cuscutae, 10 to 15 parts of raspberry and 1 to 5 parts of human placenta. The invention further relates to application of the traditional Chinese medicine composition to the preparation of a medicine for treating premature ovarian failure. The traditional Chinese medicine composition provided by the invention is small in number of ingredients, abundant in raw material, simple to prepare, and environment-friendly, and has a good application scope in curing premature ovarian failure. The prescription and the matching of the traditional Chinese medicine composition provided by the invention are obtained by screening a large number of experiments, different raw materials and the matching thereof can play a remarkable synergistic role, and the curative effect is good.

The invention discloses an endometrial stem cell and exosome combined preparation for treating endometrial injury and premature ovarian failure, and a preparation method and administration method of the endometrial stem cell and exosome combined preparation. The endometrial stem cell and exosome combined preparation comprises endometrial stem cells and an endometrial stem cell and exosome concentrated solution obtained through hunger culture. Through the method of hunger culture of the endometrial stem cells, secretion of bioactive substances of the endometrial stem cells is promoted; the bioactive substances secreted by the endometrial stem cells are recovered in an exosome form, thus the recovery efficiency is greatly improved, and the recovery mode is simpler and more convenient; and through a gradient filtration method of biofilms of different hole diameters, exosomes secreted by the endometrial stem cells are collected and concentrated, the recovery process of the exosomes is simplified, and the purity of the exosomes is improved.

A neutralizing epitope is identified within amino acids 1-3 of desacyl ghrelin. Antibodies that bind this epitope fall within the scope of the invention and can be murine, chimeric, or humanized antibodies, immunoconjugates of the antibodies, or antigen-binding fragments thereof. The antibodies of the invention are useful for the treatment or prevention of obesity and related disorders including, for example, Type II non-insulin dependent diabetes mellitus (NIDDM), Prader-Willi syndrome, eating disorders, hyperphagia, and impaired satiety. Additionally, such antibodies can be useful for the treatment or prevention of other disorders, including anxiety, gastric motility disorders (including e.g., irritable bowel syndrome and functional dyspepsia), insulin resistance syndrome, metabolic syndrome, dyslipidemia, atherosclerosis, hypertension, hyperandrogenism, polycystic ovarian syndrome, cancer, and cardiovascular disorders by administering a therapeutically effective amount of an anti-desacyl ghrelin monoclonal antibody of the invention.

The invention discloses a medicament for treating ovarian infertility, which is constituted by compound Chinese medicines. The medicine provided by the invention comprises the following medicinal components in weight proportion: epimedium herb 40-120, actinolite 30-100, root of red-rooted salvia 25-100, safflowers 25-100, motherwort herb 30-120, Chinese angelica 30-100, astragalus root 25-120, south dodder seed 30-120, common burreed rhizome 10-60, zedoary root 10-60 and twotooth achyranthes root 20-90. Experiments show that the medicament can be used for treating various diseases, such as hypo-ovarianism (inactive ovary), persistent corpus luteum, ovarian cyst, alternate follicle development, delayed ovulation and the like, and can substitute traditionally applied hormone and antibiotics medicines completely or to certain extent, therefore, the medicament is an important remedial measure indispensable to prevention and treatment of milk cow infertility.

The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating selected cancers including gynecologic cancers such as breast, ovarian, uterine and endometrial cancer and lung cancer.

The invention provides a novel fusion protein of glucagon-like peptide-1 (GLP-1) analogue and human serum albumin as well as a method for preparing the fusion protein. The composition frame of the novel fusion protein is T-S-X-G-G-H, wherein the protein sequence represented by T is a biological affinity tag; the protein sequence represented by S is a protease enzyme cutting site; X represents an amino acid; G represents GLP-1 analogue protein; H represents human serum albumin. According to the design, a GLP-1 analogue sample, of which the N end is homogeneous, is obtained through biological preparation and enzyme digestion in sequence, so that the homogeneity and activity of a biological sample are improved. The invention further provides a Chinese hamster ovary cell (CHO) stable expressing cell strain capable of stably expressing the fusion protein. The novel fusion protein is higher in biological activity and better in vivo and vitro stability, can be used for treating 2-type diabetes mellitus and other diseases capable of being treated through fasting plasma glucose reduction, can be used for treating 1-type diabetes mellitus by inducing cells to differentiate into Beta pancreatic cells, and can be further used for treating other diseases capable of being treated through nervous system irritation causing satiety generation and peristole inhibition.

The invention discloses a traditional Chinese medicine composition for treating luteal phase defect type infertility and menstrual disorder. The traditional Chinese medicine composition disclosed by the invention is prepared from the following components in parts by weight: 1-6 parts of fried radix paeoniae alba, 1-9 parts of common yam rhizome, 1-6 parts of dogwood, 0.5-3 parts of vinegar baked bupleurum root, 1-9 parts of the seed of Chinese dodder, 1.5-9 parts of sliced cornu cervi, 1.5-9 parts of amethyst and 1-6 parts of radix salviae miltiorrhizae. According to the compound composition provided by the invention, by means of syndrome differentiation and treatment, the formula is obtained through a lot of experimental screening under the guidance of theories of traditional Chinese medicines; experimental results show that the traditional Chinese medicine composition is capable of improving the structure and form of ovary mitochondria endoplasmic reticulum, improving structures of endometrial glands and mesenchyme, adjusting ovary secreted active substances E2 and P, reducing endometrium estrogen receptors and progestrone receptors and increasing expression of integrins alpha v and beta 3; therefore, the endometrium receptivity can be increased; the embryo implantation action is promoted; the traditional Chinese medicine composition has the good effect for treating infertility; and furthermore, the traditional Chinese medicine composition is free from toxic and side effect, and safe and reliable to use.

The invention relates to application of chickpea sprout extracts in medicines for preventing deficiency of estrogen. The chickpea sprout extracts are chickpea sprout isoflavone extracts, are used as estrogen receptor regulator, and are used for preparing medicines and health care products which are used for preventing or treating climacteric syndrome and osteoporosis. Tests show that the chickpea sprout isoflavone extracts can directly act onto the uterus of a patient, can remarkably increase estradiol level in blood serum, have regulating and controlling effects to a hypothalamus-hypophysis- neuroendocrine system, remarkably increase thighbone density and relative bone volume of an SD (Sprague Dawley) rat without the ovary, increase the thickness of bone trabecula, reduce separating degree of the bone trabecula, decrease the quantity of osteoclast, can alleviate bone loss of the thighbone of the rat due to the fact that the ovary of the rat is removed, increase bearing capacity of the thighbone, play an important role in regulating internal secretion conditions of middle-aged and elderly women after menopause, improving menopause symptoms such as hot flash, palpitate, skin dryness and the like and reducing possibility of osteoporosis, and lay a foundation in industrial development of functional factors of chickpeas.